---
title: "Moderna: Oddo BHF lowers target price"
description: "Oddo BHF has lowered its target price for Moderna shares from $51 to $47 while maintaining an \"outperform\" rating. This adjustment follows the discontinuation of its cytomegalovirus clinical program a"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262459845.md"
published_at: "2025-10-23T14:05:43.000Z"
---

# Moderna: Oddo BHF lowers target price

> Oddo BHF has lowered its target price for Moderna shares from $51 to $47 while maintaining an "outperform" rating. This adjustment follows the discontinuation of its cytomegalovirus clinical program after negative Phase 3 results. Despite this setback, the group's annual guidance remains unchanged, and its medium-term goal of achieving financial equilibrium by 2028 is still intact. However, the analyst notes that this discontinuation may negatively impact the stock today, as it removes a projected $4 per share contribution from the CMV vaccine.

While maintaining its "outperform" opinion on Moderna shares, Oddo BHF has lowered its target price for them from $51 to $47, following the discontinuation of its clinical program for cytomegalovirus after negative results from its Phase 3 study.

The discontinuation of the program does not impact the group's annual guidance and does not call into question its medium-term objective of achieving financial equilibrium by 2028. However, the discontinuation of this asset at an advanced stage is likely to penalize the stock today," the analyst warns.

"Moderna's challenge remains to diversify its topline. We are therefore incorporating this discontinuation into our estimates and removing the contribution of the CMV vaccine from our projections (the program represented $4 per share in our SOP)," he continues.

### Related Stocks

- [MRNA.US - Moderna](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 期权热点｜上周五 MRNA 大涨 5%，部分看涨期权飙升 213% | 美东时间 02 月 13 日，Moderna 期权总成交 194761 张，看涨期权占比 90%，看跌期权占比 9%。 | [Link](https://longbridge.com/en/news/276030129.md) |
| Moderna 获得欧洲委员会对其 COVID-19 疫苗 mNEXSPIKE 的市场授权 | Moderna 已获得欧洲委员会对其 COVID-19 疫苗 mNEXSPIKE 的市场授权，适用于 12 岁及以上的个体。这标志着 Moderna 在欧盟获得的第三款疫苗，增强了其呼吸道疫苗组合。该授权在所有 27 个欧盟成员国有效，并且 | [Link](https://longbridge.com/en/news/276120116.md) |
| Moderna 与墨西哥政府签署了为期五年的供应和制造协议 | Moderna Inc. 与墨西哥政府及当地合作伙伴签署了一项为期五年的协议，供应其呼吸道疫苗组合并进行 COVID-19 疫苗的国内生产技术转让。这项合作与墨西哥的健康主权倡议相一致，并包括当地的临床研究。该协议是在 Moderna 的  | [Link](https://longbridge.com/en/news/275453337.md) |
| 美股夜盘异动：莫德纳夜盘跌近 8%，FDA 拒审流感疫苗与分析师下调目标价双重打击 | Moderna 夜盘跌 7.89%；Recursion Pharmaceuticals 夜盘涨 1.56%，成交额达到 2.84 万美元；Viking 治疗夜盘跌 0.87%，成交额达到 1.15 万美元；ImmunityBio 成交额达到 | [Link](https://longbridge.com/en/news/275533451.md) |
| 期权热点｜周二 MRNA 大涨 17%，部分看涨期权飙升 878% | 美东时间 01 月 13 日，Moderna 期权总成交 122203 张，看涨期权占比 59%，看跌期权占比 40%。 | [Link](https://longbridge.com/en/news/272496497.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.